Just have come across this article.
The whole writing is just plain flawed.
He did not tell you that the comparison of TACTI002 VS Keynote-048 was actually 2nd line vs 1st line, and yet TACTI002 outperformed.
More importantly, talking about the Cetuximab plus chemo was good enough?
Remind you all from my previous number comparisons, on EFTI plus Keytruda in TACTI002, there is a very strong PD-L1 level dependent benefit shown, and this is chemo FREE! Such benefit is not able to achieve with any current treatment scheme. (Highlighted below)
And then saying in the 2nd line to 2nd line comparison to Keynote-040, the OS data was not so materially different.
The numbers are again highlighted here. Obviously, the journalist's capability to read paper is some what limited.
- Forums
- ASX - By Stock
- IMM
- Media
Media, page-662
-
- There are more pages in this discussion • 82 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
34.5¢ |
Change
0.005(1.47%) |
Mkt cap ! $501.1M |
Open | High | Low | Value | Volume |
34.0¢ | 34.5¢ | 32.5¢ | $659.6K | 1.969M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 399004 | 34.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
34.5¢ | 4457 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 399004 | 0.340 |
1 | 24896 | 0.335 |
3 | 179896 | 0.330 |
5 | 55615 | 0.325 |
7 | 99187 | 0.320 |
Price($) | Vol. | No. |
---|---|---|
0.345 | 4457 | 1 |
0.350 | 71896 | 5 |
0.355 | 105396 | 5 |
0.360 | 147084 | 8 |
0.365 | 178497 | 8 |
Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online